Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
about
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell linesLncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile.Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells.
P2860
Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of the putative cancer ...... nhibitors and cytotoxic drugs.
@en
Impact of the putative cancer ...... nhibitors and cytotoxic drugs.
@nl
type
label
Impact of the putative cancer ...... nhibitors and cytotoxic drugs.
@en
Impact of the putative cancer ...... nhibitors and cytotoxic drugs.
@nl
prefLabel
Impact of the putative cancer ...... nhibitors and cytotoxic drugs.
@en
Impact of the putative cancer ...... nhibitors and cytotoxic drugs.
@nl
P2093
P2860
P356
P1476
Impact of the putative cancer ...... inhibitors and cytotoxic drugs
@en
P2093
Alan M Seddon
Sharadah Essapen
Soozana Puvanenthiran
P2860
P304
P356
10.3892/IJO.2016.3678
P577
2016-09-05T00:00:00Z